Imfinzi’s perioperative approval comes after both the FDA’s staffers and a panel of external experts expressed concerns about overtreatment when using the PD-L1 blocker both before and after surgery.
Tag Archive for: lung cancer
The company announced it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was unlikely to succeed.
AstraZeneca is proposing to use Imfinzi for resectable non-small cell lung cancer in the perioperative setting—both before and after surgical resection of the tumor. However, ahead of Thursday’s advisory committee meeting, FDA staffers have expressed concerns.
Yesterday the company terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer.
Roche will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck, casting further doubt on the drug candidate pioneered by the Swiss company.
China has approved the use of AstraZeneca’s blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said today.
The blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type of early-stage lung cancer.
Pfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the strength of data presented on Friday showing most patients treated for a rare form of advanced lung cancer in a clinical trial were alive without the disease worsening after five years.
The full results, presented at the annual American Society of Clinical Oncology meeting in Chicago and published in the Journal of Clinical Oncology, show that Trodelvy reduced the risk of death by 16%, with similar improvement for harder-to-treat squamous and non-squamous types of NSCLC.
Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso.